anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: IgA nephropathy (IgAN) is a common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Outcomes are highly variable and predicting risk of disease progression at an individual level is challenging. Accurate risk stratification is important to identify individuals most likely to benefit from treatment. The Kidney Failure Risk Equation (KFRE) has been extensively validated in CKD populations and predicts the risk of ESRD at 2 and 5 years using non-invasive tests; however, its predictive performance in IgAN is unknown. The Oxford classification (OC) describes pathological features demonstrated on renal biopsy that are associated with adverse clinical outcomes that may also inform prognosis. The objective of this systematic review is to compare the KFRE with the OC in determining prognosis in IgAN.
METHODS: A systematic review will be conducted and reported in line with PRISMA guidelines (PRISMA-P checklist attached as Additional file 1). Inclusion criteria will be cohort studies that apply the KFRE or OC to determine the risk of CKD progression or ESRD in individuals with IgAN. Multiple databases will be searched in duplicate to identify relevant studies, which will be screened first by title, then by abstract and then by full-text analysis. Results will be collated for comparison. Risk of bias and confidence assessments will be conducted independently by two reviewers, with a third reviewer available if required.
DISCUSSION: Identifying individuals at the highest risk of progression to ESRD is challenging in IgAN, due to the heterogeneity of clinical outcomes. Risk prediction tools have been developed to guide clinicians; however, it is imperative that these aids are accurate and reproducible. The OC is based on observations made by specialist renal pathologists and may be open to observer bias, therefore the utility of prediction models incorporating this classification may be diminished, particularly as in the future novel biomarkers may be incorporated into clinical practice.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022364569.
System and method for monitoring the health of modules in a web-based collaboration environment are disclosed. The health monitoring system 120 identifies at least one module 108,195,196, where each module provides one or more services to clients via one or more host servers 105. In particular, the services are redundantly accessible from more than one of the plurality of modules. The health monitoring system monitors the availability status of the one or more modules, receives a query from a host server identifying a module and processes the query to determine an availability status of module. The health monitoring system then sends a response to the query to the host server. The host server(s) is configured to receive client requests 604, process the client requests to determine one or more data items, select one or more modules having the one or more data items stored thereon, and responsively transfer one or more queries requesting availability of the one or more modules to the health monitoring system. The health monitoring system is configured to periodically determine the availability status of the one or more modules. Advantageously, the monitoring of the modules is bifurcated from the host or front-end server to offload the monitoring burden.
An ophthalmic composition, containing ergocalciferol or cholecalciferol, i.e., an inactive vitamin D, as the active ingredient, for treating and conditioning damaged tissue of the region of the eye. An ophthalmic composition for preventing and treating disturbed metabolism in eye tissues, such as "dry eye", including a vitamin D or an active vitamin D as the active ingredient. An ophthalmic composition or a dermatological composition for protecting the skin or eyes from harmful ultraviolet radiation including a vitamin D or a vitamin K as the active ingredient. The ophthalmic composition normalizes the transparency or refraction of the eyeballs when administered to the region of the eye, and contributes to the amendment, healing or prevention of symptoms due to disturbed metabolism in eye tissue. The dermatological composition protects the skin and scalp from harmful ultraviolet radiation. It is possible to supply vitamin D to the skin by applying the vitamin D-containing dermatological composition via a cosmetic.
Patients receive ibrutinib as in Arm II. Patients receive rituximab IV on days 1, 8, 15, and 22 of course 2 and on day 1 of courses 3-6. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
INTRODUCTION: Obesity is currently the most common multifactorial disease affecting almost all social strata of the population. Conservative therapy of obesity usually succeeds in reducing excess weight by an average of 10-15%. After surgical treatment of severe obesity (bariatric surgery), the average decrease in excess weight is several times greater and, in most cases, has a long-term positive effect on the overall clinical condition of the patients.
METHODS: Sleeve gastrectomy (SG) is the most used bariatric method of treating severe obesity today. The principle of SG is a vertical resection of a major portion of the gastric greater curvature. After the resection, the residual stomach has the shape of a sleeve with a remaining volume of about 120-150 ml. The effect of the method is both restrictive and hormonal, because after SG, the plasma level of active ghrelin decreases in the long term, among other things.
CONCLUSION: Obesity is considered one of the most serious global health problems today. In 2018 a total of 696,191 bariatric procedures were performed worldwide. Sleeve gastrectomy was originally used in high-risk severely obese patients as the first stage of a duodenal switch (DS) or gastric bypass. Since 2003, this method has been used independently because for most of the patients, SG had a sufficient effect on weight reduction and improvement of comorbidities, and that is why since 2015, SG has become the most frequently used bariatric method.
The invention relates to an application of Lycojaponicumin B in the preparation of medicines for resisting human body fungi, belonging to the field of medicines. The Lycojaponicumin B has very strong inhibitory effect on trichophyton rubrum, microsporum lanosum or trichophyton tonsurans. Therefore, the Lycojaponicumin B can serve as a compound capable of resisting human body fungi and is expected to be applied in the preparation of related medicines. The application of the Lycojaponicumin B in the preparation of the medicines for resisting human body fungi is disclosed for the first time. As the skeleton type of the Lycojaponicumin B belongs to a brand-new skeleton type, the Lycojaponicumin B has unexpected strong inhibitory activity on human body fungi, and the possibility that other compounds provide revelation does not exist. The Lycojaponicumin B has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for preventing and treating human body fungi infection.
After tens of years of studying, researching and continuous experimenting, the inventor develops the tinea-sore-removing ointment. The ointment is mainly used for treating skin diseases such as beriberi and impetiginous sores. The main components of the ointment include: lead tetroxide, dried alum, vaseline, lanolin, and the like. The components are prepared into the medicine ointment according to a certain ratio. Every 10g of the ointment is prepared from 0.1g of lead tetroxide, 0.1g of dried alum, 0.3g of lanolin, 0.5g of vaseline, and 0.5g of erythromycin. The 10g of the ointment is filled in a small box, and is ready to be used. Treatments are carried out according to the pathogenetic condition, the treatment course, and a certain dosage. For treating beriberi, a treatment course comprises 7days, and the patient can recover within approximately 1 month. For treating impetiginous sores, 2-3 treatment courses should be added.
Tight glycemic control may improve tuberculosis (TB) treatment outcome and help reduce symptoms. However, active TB and TB treatment hamper glycemic control. Patients starting TB treatment experience rapid changes in appetite, body composition, and inflammation (which increases insulin resistance); inflammation is a feature of untreated TB and following an increase as a result of initial bacterial killing, inflammation subsides with successful treatment. In addition, TB medication (rifampicin) increases the metabolism of oral anti-diabetic drugs including the widely used sulphonylureas and thiazolidinediones, though a possible interaction with the antidiabetic drug metformin has not been previously examined. Frequent monitoring of blood glucose with adjustments in anti-diabetes medication during the course of TB treatment may therefore be needed. However, frequent monitoring is associated with additional costs, and tools and skills for glucose monitoring and diabetes treatment may be lacking in TB or pulmonary clinics, creating a need to refer patients to other health providers. As such, a less intense schedule, preferably following the established decision points in TB treatment after 2 and 6 months would offer significant advantage. None of these issues have been addressed systematically so far.
High salt consumption is an important determinant of high blood pressure (BP) and cardiovascular diseases. Several intervention studies showed that a reduction in salt consumption reduces BP and can reduce cardiovascular risk beyond the beneficial effect on BP in people with and without hypertension. The World Health Organization (WHO) recommends that adults should consume no more than 5 g of salt daily. However, the mean daily intake of salt in the majority of countries worldwide exceeds this recommendation. In contrast to salt, epidemiological and intervention studies suggest beneficial effects of dietary potassium on BP and cardiovascular risk. This effect seems more pronounced during high salt consumption. The WHO currently also recommends that adults should consume not less than 90 mmol of potassium daily. However, also for potassium the WHO recommendations are not generally met.

Several countries have made some progress towards reducing habitual salt intake through a voluntary or regulatory approach, achieving a reduction of BP and cardiovascular disease in the young population. Our previous observational data detected that Italian general population samples consumed high dietary salt and low dietary potassium, far from the WHO guidelines recommendation. Excess dietary salt intake in the hypertensive patients' population was observed in all age categories and there were no differences in salt intake among different regions. Likewise, in the same hypertensive population the adequate potassium intake in both men and women, in all age categories, and in all the regions surveyed was much below the recommendation. These results point out the potential target to improve BP and cardiovascular risk, in particular in hypertensive patients. An Italian survey of a large cohort of the general population showed that the degree of knowledge and behaviour about salt was directly interrelated. These data suggested that educational approach is crucial to improve the level of salt consumption. The reduction of salt intake has been recommended by WHO as a cost-effective action that should be undertaken. Hence, an intervention study targeted to reduce dietary salt intake and also to increase dietary potassium consumption by an educational intervention is needed.

Given these premises, the aim of the present intervention study will be to evaluate the effect of a brief educational intervention "MINIMAL-ADVICE" for improving dietary salt and potassium intake in a hypertensive population. In addition, the effect of the educational intervention on BP in relation to the potential variation of salt and potassium intake will be also evaluated.
<P>PROBLEM TO BE SOLVED: To obtain a fat cell differentiation promoter that is taken as a safe food every day in spite of having promoting action on fat cell differentiation.  <P>SOLUTION: The fat cell differentiation promoter from a fat cell precursor to fat cell comprises a component extracted from Matico as an active ingredient. The fat cell differentiation promoter from an enlarged fat cell to a small-sized normal fat cell comprises the component extracted from Matico as an active ingredient. The visceral fat increase inhibitor comprises the component extracted from Matico as an active ingredient. The agent for preventing and ameliorating life style-related diseases followed by adipocytokine secretion abnormality comprises the component extracted from Matico as an active ingredient. The agent for preventing and ameliorating diseases through a transcription factor related to fat cell differentiation comprises the component extracted from Matico as an active ingredient.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Pregnancy Category D:  Efavirenz may cause fetal harm when administered during the first trimester to a pregnant woman. Pregnancy should be avoided in women receiving ATRIPLA. Barrier contraception must always be used in combination with other methods of contraception (e.g., oral or other hormonal contraceptives). Because of the long half-life of efavirenz, use of adequate contraceptive measures for 12 weeks after discontinuation of ATRIPLA is recommended. Women of childbearing potential should undergo pregnancy testing before initiation of ATRIPLA. If this drug is used during the first trimester of pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

There are no adequate and well-controlled studies of ATRIPLA in pregnant women. ATRIPLA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, such as in pregnant women without other therapeutic options.
The injection procedure should be carried out under controlled aseptic conditions, which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.

Following the injection, patients should be monitored for elevation in intraocular pressure (IOP) and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay.

Each vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, and injection needles should be changed before TRIESENCE suspension is administered to the other eye.
Sensory deprivation theory is an important hypothesis involving potential pathways between hearing loss and cognitive impairment in patients with presbycusis. The theory suggests that prolonged auditory deprivation in presbycusis, including neural deafferentation, cortical reallocation, and atrophy, causes long-lasting changes and reorganization in brain structure and function. However, neurophysiological changes underlying the cognition-ear link have not been explored. In this study, we recruited 98 presbycusis patients and 60 healthy controls and examined the differences between the two groups in gamma-aminobutyric acid (GABA) and glutamate (Glu) levels in bilateral auditory cortex, excitation-inhibition (E/I) balance (Glu/GABA ratio), dynamic functional network connectivity (dFNC), hearing ability and cognitive performance. Then, correlations with each other were investigated and variables with statistical significance were further analyzed using the PROCESS Macro in SPSS. GABA levels in right auditory cortex and Glu levels in bilateral auditory cortex were lower but E/I balance in right auditory cortex were higher in presbycusis patients compared to healthy controls. Hearing assessments and cognitive performance were worse in presbycusis patients. Three recurring connectivity states were identified after dFNC analysis: State 1 (least frequent, middle-high dFNC strength with negative functional connectivity), State 2 (high dFNC strength), and State 3 (most frequent, low dFNC strength). The occurrence and dwell time of State 3 were higher, on the other hand, the dwell time of State 2 decreased in patients with presbycusis compared to healthy controls. In patients with presbycusis, worse hearing assessments and cognition were correlated with decreased GABA levels, increased E/I balance, and aberrant dFNC, decreased GABA levels and increased E/I balance were correlated with decreased occurrence and dwell time in State 3. In the mediation model, the fractional windows, as well as dwell time in State 3, mediated the relationship between the E/I balance in right auditory cortex and episodic memory (Auditory Verbal Learning Test, AVLT) in presbycusis. Moreover, in patients with presbycusis, we found that worse hearing loss contribute to lower GABA levels, higher E/I balance, and further impact aberrant dFNC, which caused lower AVLT scores. Overall, the results suggest that a shift in E/I balance in right auditory cortex plays an important role in cognition-ear link reorganization and provide evidence for sensory deprivation theory, enhancing our understanding the connection between neurophysiological changes and cognitive impairment in presbycusis. In presbycusis patients, E/I balance may serve as a potential neuroimaging marker for exploring and predicting cognitive impairment.
A cosmetic hair preparation which is effective in preventing the hair from creaking during rinsing in a water stream, and in improving the flexibility and smoothness of the hair being rinsed and which thereby prevents the hair from being damaged by hair entanglement during rinsing. It contains an organopolysiloxane having an amino-modified organopolysiloxane chain and a polyoxyalkylene chain and at least one cationic surfactant selected among compounds represented by the general formulae (1) and (2). [In the formulae, at least one of R 1 , R 2 , R 3 , and R 4  represents alkyl having 8 to 35 carbon atoms in total, etc. and the remainder represent C 1-5  alkyl or hydroxyalkyl, etc.; X -  represents a halogen ion or organic anion; R 5  represents alkyl having 8 to 35 carbon atoms in total, etc.; and R 6  represents C 1-22  alkyl, etc.]
In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea and hypophonia, were observed. In a life-threatening case of immune-mediated myositis, symptoms resolved during hospitalization following additional immunomodulatory treatment; muscle strength gradually improved but did not return to baseline level. These immune reactions may be due to a T-cell based response from lack of self-tolerance to a specific region encoded by the transgene corresponding to exons 1-17 of the DMD gene. 

Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71 [see Clinical Studies (14)]. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene due to the increased risk for a severe immune-mediated myositis reaction [see Contraindications (4)]. 

Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea or hypophonia as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur.
Posttreatment Exacerbations of Hepatitis: In clinical trials in non-HIV-1-infected patients treated with lamivudine for chronic HBV, clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of lamivudine. These exacerbations have been detected primarily by serum ALT elevations in addition to re-emergence of hepatitis B viral DNA (HBV DNA). Although most events appear to have been self-limited, fatalities have been reported in some cases. Similar events have been reported from postmarketing experience after changes from lamivudine-containing HIV-1 treatment regimens to non-lamivudine-containing regimens in patients infected with both HIV-1 and HBV. The causal relationship to discontinuation of lamivudine treatment is unknown. Patients should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. There is insufficient evidence to determine whether re-initiation of lamivudine alters the course of posttreatment exacerbations of hepatitis.

Important Differences Among Lamivudine-Containing Products: Lamivudine and zidovudine tablets contain a higher dose of the same active ingredient (lamivudine) than EPIVIR-HBV® (lamivudine) Tablets and Oral Solution. EPIVIR-HBV was developed for treating chronic hepatitis B. Safety and efficacy of lamivudine have not been established for treatment of chronic hepatitis B in patients co-infected with HIV-1 and HBV. 

Emergence of Lamivudine-Resistant HBV: In non-HIV-infected patients treated with lamivudine for chronic hepatitis B, emergence of lamivudine-resistant HBV has been detected and has been associated with diminished treatment response (see full prescribing information for EPIVIR-HBV for additional information). Emergence of hepatitis B virus variants associated with resistance to lamivudine has also been reported in HIV-1-infected patients who have received lamivudine-containing antiretroviral regimens in the presence of concurrent infection with hepatitis B virus.
A method of treating skin disorders using a extract from the plant Mullein (genus Verbascum) and a composition including an extract from the plant Mullein (genus Verbascum) are described. The extract is obtained by cooking the leaves and roots of the plant Mullein in a pressure cooker with water. The resulting liquid extract is canned according to standard home canning procedures. The method is accomplished by applying the liquid extract to affected areas of the skin twice daily. Most subjects experience positive results within a period of approximately two weeks. Skin disorders that have been treated using this extract include the sun exposure related skin disorders, actinic keratoses, lentigines, seborrheic keratoses, and the inflammatory skin disorders including prurigo, psoriasis, and contact dermatitis. The skin cancer, malignant melanoma, has also been treated using this method.
PROBLEM TO BE SOLVED: To obtain a cataplasm for stiff shoulder and frozen shoulder syndrome which contains a specific amount of lidocaine (or its salt) in an ointment bace, develops marked treatment effect on stiff shoulder and frozen shoulder syndrome and is also useful as a nonproprietary drug. SOLUTION: This cataplasm contains 0.5-5wt.%, preferably 0.5-2wt.% of lidocaine or its salt in its ointment base. As a salt of lidocaine, its hydrochloride can be cited. The cataplasm is in the form of tapes, poultice and the like. A tape preparation is produced, for example, by admixing lidocaine or its salt to an acrylic ester tacky agent to prepare an ointment and applying the ointment to a flexible substrate such as polyolefin film. A poultice is prepared, for example, by admixing lidocaine or its salt to an adhesive mainly comprising a water-soluble polymer of high water retention such as methlcellulose or its salt and spreading the mixture on the substrate such as nonwoven fabric and covering the ointment surface with a plastic film.